Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3274231 | Médecine des Maladies Métaboliques | 2015 | 13 Pages |
Abstract
LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
M. Marre, S.P. Marso, N.R. Poulter, S.E. Nissen, M.A. Nauck, B. Zinman, G.H. Daniels, S. Pocock, W.M. Steinberg, R.M. Bergenstal, J.F.E. Mann, L. Steen Ravn, K. Brown Frandsen, A.C. Moses, J.B. Buse,